{"nctId":"NCT00116142","briefTitle":"Hormone Suppression and Radiation Therapy for 6 Months With/Without Docetaxel for High Risk Prostate Cancer","startDateStruct":{"date":"2005-06"},"conditions":["Prostate Cancer"],"count":350,"armGroups":[{"label":"Arm1: Androgen Suppression Therapy + Radiation Therapy","type":"OTHER","interventionNames":["Drug: Androgen Hormonal Suppression and Radiation","Drug: Androgen Suppression Therapy and Radiation Therapy"]},{"label":"Arm 2: Docetaxel + Androgen Suppression Therapy + Radiation Therapy","type":"EXPERIMENTAL","interventionNames":["Drug: Docetaxel","Drug: Androgen Hormonal Suppression and Radiation","Drug: Androgen Suppression Therapy and Radiation Therapy"]}],"interventions":[{"name":"Docetaxel","otherNames":["Taxotere"]},{"name":"Androgen Hormonal Suppression and Radiation","otherNames":[]},{"name":"Androgen Suppression Therapy and Radiation Therapy","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Biopsy proven prostate cancer\n* Clinical Tumor Category T1b, T1c, T2a and PSA greater than (\\>) 10 or Gleason score equal or greater than 4+3=7 or PSA velocity \\> 2.0 ng/ml per year and also eligible patients with tumor category T2c, T3a, T3b, or T4 as per 2002 AJCC guidelines. Any minor tertiary grade of Gleason 5; Biopsy Proven or Radiographic (erMRI Seminal Vesicle Invasion); Gleason = or \\> 3+4=7 with 50% or more cores positive\n* Negative bone scan\n* Lymph node assessment by CT or MR\n* Adequate hematologic function (Blood Counts)\n* Adequate liver functions (blood tests)\n* ECOG performance Status 0 or 1\n* Peripheral neuropathy must be =\\< grade 1\n* PSA obtained within 3 months of entry\n\nExclusion Criteria:\n\n* Prior history of malignancy that are \\< 5 years except for cancers found to be \"in-situ\" and would not likely impact a patient's life expectancy with appropriate medical management.\n* Prior pelvic radiation therapy\n* Prior hormonal therapy (up to 4 weeks prior to enrollment allowed)\n* Individuals unable to tolerate lying still 5 - 10 minutes\n* Patients with a history of severe hypersensitivity reaction to docetaxel or other drugs formulated with polysorbate 90.","healthyVolunteers":false,"sex":"MALE","minimumAge":"30 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"10-Year Restricted Mean Survival Time for Overall Survival","description":"Overall survival (OS) was measured from the date of random assignment to death from any cause, censored at the date of last follow-up in surviving patients. The 10-Year Restricted Mean Survival Time was calculated as the area under the Kaplan Meier plot for OS, from randomization to 10-years follow-up","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.82","spread":"0.19"},{"groupId":"OG001","value":"9.11","spread":"0.15"}]}]}]},{"type":"SECONDARY","title":"10-year Biochemical Recurrence (PSA Failure)","description":"Time to biochemical recurrence was defined as the time from date of random assignment to the earliest of PSA failure or initiation of salvage therapy, or censored at the date of last disease assessment for those without PSA failure. PSA failure was defined according to the 2006 RTOG-ASTRO Phoenix definition (i.e., A PSA rise by 2 ng/mL or more above the nadir).\n\n10-year biochemical recurrence rate was estimated from a competing risk model where non-prostate cancer death was counted as competing risk.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"48","spread":null},{"groupId":"OG001","value":"54","spread":null}]}]}]},{"type":"SECONDARY","title":"10-year Prostate Cancer Mortality","description":"Measured from the date of random assignment to date of death from prostate cancer, or censored at the date of last follow-up in surviving patients. Patients who died due to other reasons were counted as competing risk in a competing risk model.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"15","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Acute Adverse Events","description":"Adverse acute events were reported via the clinical database only for toxicities considered reportable via the SAE mechanism (those of grade 2 and grade 3 events that are unexpected and possibly, probably, or definitely related/associated with treatment; or all grade 4 and grade 5 events). Common Toxicity Criteria Volume 3.0 (CTCAE) is used for this study.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18","spread":null},{"groupId":"OG001","value":"46","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Late Adverse Events, Any Grade and Attribution","description":"Late adverse events will be focused on GU/GI including Urinary/Fecal Incontinence, Hematuria, Diarrhea, Rectal Bleeding and other.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"128","spread":null},{"groupId":"OG001","value":"140","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":63,"n":174},"commonTop":["Renal/GU-other","Urinary frequency/urgency","Diarrhea w/o prior colostomy","Rectum, hemorrhage","Incontinence urinary"]}}}